Literature DB >> 3095375

Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

H N Ginsberg, N A Le, I J Goldberg, J C Gibson, A Rubinstein, P Wang-Iverson, R Norum, W V Brown.   

Abstract

Previous data suggest that apolipoprotein (apo) CIII may inhibit both triglyceride hydrolysis by lipoprotein lipase (LPL) and apo E-mediated uptake of triglyceride-rich lipoproteins by the liver. We studied apo B metabolism in very low density (VLDL), intermediate density (IDL), and low density lipoproteins (LDL) in two sisters with apo CIII-apo AI deficiency. The subjects had reduced levels of VLDL triglyceride, normal LDL cholesterol, and near absence of high density lipoprotein (HDL) cholesterol. Compartmental analysis of the kinetics of apo B metabolism after injection of 125I-VLDL and 131I-LDL revealed fractional catabolic rates (FCR) for VLDL apo B that were six to seven times faster than normal. Simultaneous injection of [3H]glycerol demonstrated rapid catabolism of VLDL triglyceride. VLDL apo B was rapidly and efficiently converted to IDL and LDL. The FCR for LDL apo B was normal. In vitro experiments indicated that, although sera from the apo CIII-apo-AI deficient patients were able to normally activate purified LPL, increasing volumes of these sera did not result in the progressive inhibition of LPL activity demonstrable with normal sera. Addition of purified apo CIII to the deficient sera resulted in 20-50% reductions in maximal LPL activity compared with levels of activity attained with the same volumes of the native, deficient sera. These in vitro studies, together with the in vivo results, indicate that in normal subjects apo CIII can inhibit the catabolism of triglyceride-rich lipoproteins by lipoprotein lipase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3095375      PMCID: PMC423815          DOI: 10.1172/JCI112713

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement.

Authors:  P R Finley; R B Schifman; R J Williams; D A Lichti
Journal:  Clin Chem       Date:  1978-06       Impact factor: 8.327

3.  Effect of serum and C-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase.

Authors:  P K Kinnunen; C Ehnolm
Journal:  FEBS Lett       Date:  1976-06-15       Impact factor: 4.124

4.  Direct measurement of apoprotein B specific activity in 125I-labeled lipoproteins.

Authors:  N A Le; J S Melish; B C Roach; H N Ginsberg; W V Brown
Journal:  J Lipid Res       Date:  1978-07       Impact factor: 5.922

5.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.

Authors:  D W Bilheimer; S Eisenberg; R I Levy
Journal:  Biochim Biophys Acta       Date:  1972-02-21

6.  Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein.

Authors:  W V Brown; M L Baginsky
Journal:  Biochem Biophys Res Commun       Date:  1972-01-31       Impact factor: 3.575

7.  Cholesterol esterase in rat adipose tissue and its activation by cyclic adenosine 3':5'-monophosphate-dependent protein kinase.

Authors:  R C Pittman; J C Khoo; D Steinberg
Journal:  J Biol Chem       Date:  1975-06-25       Impact factor: 5.157

8.  Post-heparin plasma lipoprotein lipase and hepatic lipase in normal subjects and in patients with hypertriglyceridaemia: correlations to sex, age and various parameters of triglyceride metabolism.

Authors:  J K Huttunen; C Ehnholm; M Kekki; E A Nikkilä
Journal:  Clin Sci Mol Med       Date:  1976-04

9.  Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia.

Authors:  S M Grundy; H Y Mok; L Zech; D Steinberg; M Berman
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

10.  Simple liquid-liquid partition system for isolation of labeled oleic acid from mixtures with glycerides.

Authors:  P Belfrage; M Vaughan
Journal:  J Lipid Res       Date:  1969-05       Impact factor: 5.922

View more
  113 in total

1.  The apolipoprotein CIII T2854G variants are associated with postprandial triacylglycerol concentrations in normolipidemic Korean men.

Authors:  Sang-Koo Woo; Hyun-Sik Kang
Journal:  J Hum Genet       Date:  2003-09-27       Impact factor: 3.172

Review 2.  Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

Authors:  Jacqueline de Graaf; Mario J Veerkamp; Anton F H Stalenhoef
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

3.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 4.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 5.  Role of bile acids in the regulation of the metabolic pathways.

Authors:  Hiroki Taoka; Yoko Yokoyama; Kohkichi Morimoto; Naho Kitamura; Tatsuya Tanigaki; Yoko Takashina; Kazuo Tsubota; Mitsuhiro Watanabe
Journal:  World J Diabetes       Date:  2016-07-10

6.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

7.  A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.

Authors:  Toni I Pollin; Coleen M Damcott; Haiqing Shen; Sandra H Ott; John Shelton; Richard B Horenstein; Wendy Post; John C McLenithan; Lawrence F Bielak; Patricia A Peyser; Braxton D Mitchell; Michael Miller; Jeffrey R O'Connell; Alan R Shuldiner
Journal:  Science       Date:  2008-12-12       Impact factor: 47.728

8.  Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.

Authors:  Ranjan Chakrabarti; Reeba K Vikramadithyan; Parimal Misra; Jagadheshan Hiriyan; Suryaprakash Raichur; Ravi K Damarla; Cynthia Gershome; Juluri Suresh; Ramanujam Rajagopalan
Journal:  Br J Pharmacol       Date:  2003-09-01       Impact factor: 8.739

Review 9.  The role of hypertriglyceridemia in atherosclerosis.

Authors:  Ngoc-Anh Le; Mary F Walter
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

Review 10.  Omega-3 fatty acid supplementation and cardiovascular disease.

Authors:  Donald B Jump; Christopher M Depner; Sasmita Tripathy
Journal:  J Lipid Res       Date:  2012-08-17       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.